ijms-logo

Journal Browser

Journal Browser

Special Issue "Breast Cancer Mechanistic Insights and Targeted Therapies"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: 15 December 2021.

Special Issue Editors

Dr. Cornelia Braicu
E-Mail Website
Guest Editor
Research Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 23 Marinescu Street, 400337 Cluj-Napoca, Romania
Interests: breast cancer; drug discovery; drug resistance; functional genomics; nutrigenomics; personalized medicine
Special Issues and Collections in MDPI journals
Dr. Ancuta Jurj
E-Mail Website
Co-Guest Editor
Research Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 23 Marinescu Street, 400337 Cluj-Napoca, Romania
Interests: extracellular vesicles; 3D cultures; drug resistance; breast cancer
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues

Breast cancer remains the most frequent cancer in women and at the same time is a highly heterogeneous disease, reflected on the different prognostic and treatment response rates.

Our special issue focus on the identification of biomarkers that underline the oncogenic signaling networks in breast cancer.  A particular focus will be on the discovery of novel mechanistic insights for a personalized cancer treatment, and discovery and test of novel targeted therapies, preventing activation of drug resistance mechanisms for each individual breast cancer subtype.

The objective of the current Special Issue in IJMS is to publish original research papers and reviews of authors interested in addressing these challenges and to cover all the latest and outstanding development in the field of breast cancer.

Dr. Cornelia Braicu
Dr. Ancuta Jurj
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • molecular mechanism
  • biomarkers
  • oncogenic signaling pathways
  • targeted therapies

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Targeting Lipocalin-2 in Inflammatory Breast Cancer Cells with Small Interference RNA and Small Molecule Inhibitors
Int. J. Mol. Sci. 2021, 22(16), 8581; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22168581 - 10 Aug 2021
Viewed by 493
Abstract
Inflammatory Breast Cancer (IBC) is an aggressive form of invasive breast cancer, highly metastatic, representing 2–4% of all breast cancer cases in the United States. Despite its rare nature, IBC is responsible for 7–10% of all breast cancer deaths, with a 5-year survival [...] Read more.
Inflammatory Breast Cancer (IBC) is an aggressive form of invasive breast cancer, highly metastatic, representing 2–4% of all breast cancer cases in the United States. Despite its rare nature, IBC is responsible for 7–10% of all breast cancer deaths, with a 5-year survival rate of 40%. Thus, targeted and effective therapies against IBC are needed. Here, we proposed Lipocalin-2 (LCN2)—a secreted glycoprotein aberrantly abundant in different cancers—as a plausible target for IBC. In immunoblotting, we observed higher LCN2 protein levels in IBC cells than non-IBC cells, where the LCN2 levels were almost undetectable. We assessed the biological effects of targeting LCN2 in IBC cells with small interference RNAs (siRNAs) and small molecule inhibitors. siRNA-mediated LCN2 silencing in IBC cells significantly reduced cell proliferation, viability, migration, and invasion. Furthermore, LCN2 silencing promoted apoptosis and arrested the cell cycle progression in the G0/G1 to S phase transition. We used in silico analysis with a library of 25,000 compounds to identify potential LCN2 inhibitors, and four out of sixteen selected compounds significantly decreased cell proliferation, cell viability, and the AKT phosphorylation levels in SUM149 cells. Moreover, ectopically expressing LCN2 MCF7 cells, treated with two potential LCN2 inhibitors (ZINC00784494 and ZINC00640089) showed a significant decrease in cell proliferation. Our findings suggest LCN2 as a promising target for IBC treatment using siRNA and small molecule inhibitors. Full article
(This article belongs to the Special Issue Breast Cancer Mechanistic Insights and Targeted Therapies)
Show Figures

Figure 1

Back to TopTop